Retension Pharmaceuticals Announces Pricing of Initial Public Offering

Retension Pharmaceuticals, a clinical-stage biopharmaceutical company developing treatments for hypertension and cardiovascular diseases, priced its IPO at $12 per share, raising $45 million gross proceeds. The company plans to use the funds to complete Phase 2b trials and prepare for Phase 3 trials of its lead candidate RTN-001. Trading on Nasdaq under ticker RTSN is expected to begin October 9, 2026.